Clinical Study on Treatment of L-DOPA-Induced Dyskinesia With Tianqi Pingchan Granule Combined With Amantadine

Exclusion Criteria

• •1. PD patients with biphasic, dystonia, closure, myoclonus, but no dyskinesia;
• •2. pregnant and lactating women;
• •3. Taking other Chinese medicines against Parkinson's disease 2 weeks before enrollment;
• •4. Impaired cognitive function (according to pre-entry MMSE score): secondary education level: MMSE \<24 points; primary education level \<20 points; illiterate \<17 points;
• •5. Psychiatric symptoms associated with anti-Parkinson's disease drugs
• •6. accompanied by a history of mental illness;
• •7. impaired liver and kidney function;
• •8. accompanied by severe other systemic diseases;
• •9. Amantadine treatment has been received within the first 30 days of enrollment;
• •10. History of medication with apomorphine or dopamine receptor antagonists;
• •11. Previously taking amantadine, unable to tolerate;
• •12. Allergic to the amantadine, memantine, and traditional Chinese medicine preparations or serious adverse reactions;
• •13. Before the enrollment, the EKG showed obvious abnormalities and required clinical intervention.
• •14. has received PD-related brain surgery;
• •15. Patients who are participating in other clinical studies or have participated in other clinical studies within the previous 30 days;
• •16. Patients who are unable to follow up with follow-up.